Delivering timely service and evidence-informed resources to people in BC and the Yukon facing cancer and those involved in oncology care or research.
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency PG Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency SUR Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency KEL Cancer Info Ctr | Available |
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.3 BC Cancer Agency VIC Cancer Info Ctr | Available |
Table of Contents:; 1. Radiation Dermatitis -- 2. Hair Loss -- 3. Radiation Brain Injury -- 4. Radiation Orbital Toxicity -- 5. Ear Toxicity -- 6. Oral Mucositis -- 7. Xerostomia -- 8. Loss of Taste -- 9. Laryngeal Edema -- 10. Radiation Pneumonitis -- 11. Pericarditis -- 12. Esophagitis -- 13. Ra…
c.1 BC Cancer Agency KEL Library | Available |
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available |
c.1 BC Cancer Agency VAN Library REF | Available | ||
c.2 BC Cancer Agency VAN Library REF | Available | ||
c.1 BC Cancer Agency SUR Library REF | Available | ||
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available |
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available |
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available |
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available |
c.1 BC Cancer Agency VAN Library | Available |
Pamphlet and bookmark
Table of Contents:; Introduction; Here to help; Your child - the initial diagnosis; Your child - coping with change; Parents - coming to terms with your feelings; Siblings - helping them cope too; Communicating with your extended family and friends; The new normal; More information
"Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia…